Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The cost-effectiveness of isavuconazole compared to voriconazole, the standard of care in the treatment of patients with invasive mould diseases, prior to differential pathogen diagnosis in Spain.
Azanza JR, Grau S, Vázquez L, Rebollo P, Peral C, López-Ibáñez de Aldecoa A, López-Gómez V. Azanza JR, et al. Among authors: peral c. Mycoses. 2021 Jan;64(1):66-77. doi: 10.1111/myc.13189. Epub 2020 Oct 30. Mycoses. 2021. PMID: 32989796 Free PMC article.
Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain.
Taxonera C, de Andrés-Nogales F, García-López S, Sánchez-Guerrero A, Menchén B, Peral C, Cábez A, Gómez S, López-Ibáñez de Aldecoa A, Casado MÁ, Menchén L. Taxonera C, et al. Among authors: peral c. Expert Rev Pharmacoecon Outcomes Res. 2022 Jan;22(1):73-83. doi: 10.1080/14737167.2021.1880324. Epub 2021 Feb 20. Expert Rev Pharmacoecon Outcomes Res. 2022. PMID: 33615953
Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain.
Galan L, Gonzalez-Moreno J, Martínez-Sesmero JM, Muñoz-Beamud F, Santos-Rubio MD, Tran D, Lebeau P, Stewart M, Mallaina P, Tarilonte P, Peral C, Rozenbaum MH. Galan L, et al. Among authors: peral c. Expert Rev Pharmacoecon Outcomes Res. 2021 Oct;21(5):967-973. doi: 10.1080/14737167.2021.1900738. Epub 2021 Mar 24. Expert Rev Pharmacoecon Outcomes Res. 2021. PMID: 33724140 Free article.
Cost effectiveness analysis of fesoterodine compared to mirabegron in first-line therapy setting for overactive bladder with urge urinary incontinence, from the Spanish National Health System perspective.
Angulo JC, Sánchez-Ballester F, Peral C, Rejas J, Ramos J, Snedecor SJ, Sudharshan L, Liu S, Luo X. Angulo JC, et al. Among authors: peral c. Actas Urol Esp. 2016 Oct;40(8):513-22. doi: 10.1016/j.acuro.2015.11.012. Epub 2016 Mar 14. Actas Urol Esp. 2016. PMID: 26988624 English, Spanish.
Cost-effectiveness analysis of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis in Spain.
Grau S, Azanza JR, Ruiz I, Vallejo C, Mensa J, Maertens J, Heinz WJ, Barrueta JA, Peral C, Mesa FJ, Barrado M, Charbonneau C, Rubio-Rodríguez D, Rubio-Terrés C. Grau S, et al. Among authors: peral c. Clinicoecon Outcomes Res. 2016 Dec 30;9:39-47. doi: 10.2147/CEOR.S122177. eCollection 2017. Clinicoecon Outcomes Res. 2016. PMID: 28115858 Free PMC article.
26 results